期刊文献+

大剂量重组人促红细胞生成素对肾性贫血患者骨髓象及铁代谢的研究 被引量:2

The Effect of High Dose of rHuEPO for Renal Anemian on Bone Marrow and Iron Metabolism
在线阅读 下载PDF
导出
摘要 目的观察应用大剂量重组人促红细胞生成素(rHuEPO)治疗肾性贫血时患者的骨髓象在治疗前后的变化,探讨rHuEPO对肾性贫血患者骨髓和铁代谢的影响。方法对35例肾性贫血患者给予1万IU rHuEPO皮下注射,每周1次,连续4周,在治疗前后分别行骨髓显微成像分析和铁染色;分别检测血象中RBC, Hb,Hct,Ret%;检测血清铁,SF和骨髓像中E%,G/E,外铁、铁粒幼细胞并进行自身对照。结果35例中显效10 例、有效7例,总有效率48.57%.22例治疗后红系骨髓象增生活跃程度比治疗前明显增强(P<0.01),且增幅高于红系血象各项指标,而血清铁、SF、外铁、铁粒幼细胞均显著降低。结论rHuEPO治疗肾性贫血疗效显著,骨髓红系增生显著,随着骨髓造血增强,大量机体储存铁被利用。 Objective To study the effect of high dose of rHuEPO for renal anemian on bone marrow and iron metabolism . Methods Thirty-five patients with renal anemia received treatment of high dose of rHuEPO injection subcutaneous for 4 weeks, bone marrow aepiration was performed within the first day of admission and repeated 4 weeks later, observe the variation of erythro percent, sideroblast counts, RBC, Hb, Hct, Ret count, serum ferritin and serurn iron before and after the therapy. Results After the therapy, the E% , RBC, Hb, Hct and Ret count increased significantly, bone marrow iron deposits decreased progressively as Hct increased. Conclusion rHuEPO is effective in treatment of renal anemia, with the expansion of the red cell mass, a great lot of deposited iron was utilized.
出处 《潍坊医学院学报》 2005年第2期86-89,共4页 Acta Academiae Medicinae Weifang
关键词 重组人促红细胞生成素 肾性贫血 骨髓象 铁代谢 Recombined human erythropoietin Renal anemi Bone marrow Iron metabolism
  • 相关文献

参考文献13

  • 1郑法雷,李莉,谌贻璞,陈香美,王质刚,唐政,陆福明,王梅,于仲元.应用重组人红细胞生成素注射液(宁红欣)治疗肾性贫血的多中心临床试验报告[J].中国血液净化,2002,1(5):5-8. 被引量:16
  • 2袁群生,郑法雷,丁峰,姜筠,郭王,黄峰先,王质刚,余学清,谌贻璞,顾勇,单渊东.蔗糖铁注射液治疗血液透析患者肾性贫血的多中心研究[J].中华肾脏病杂志,2004,20(1):51-55. 被引量:117
  • 3Vanrenterghem Y, Barany P, Johannes F E et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients[J]. Kid Int ,2002,62(21) :2 167 ~2 175.
  • 4Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombination human erythropoietin[ J ]. New Engl J Med, 1987,316( 1 ): 73 ~ 78.
  • 5National kidney foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification [ J ]. Am J Kid Dis ,2002,39( supp1 ) :261 ~ 266.
  • 6Mayeux P, Billat C, Jaccquot R. The erythropoietin receptor of rat erytheroid progenitor cell characterization and affinity cross-linkage[J]. J Biol Chem,1987,262(161):13 985 ~ 13 990.
  • 7Moreno F, Sanz-Guaajardo D, Lopez-Gomez JM, et al. Increasing the hemotocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish cooperative renal patients quality of life study group of the spanish society of nephrology[J]. J AM Soc Nephrol, 2000, 11 (3):335 ~ 342.
  • 8John C. Benefits of anemia treatment on cognitive function[ J ]. Nephrol Dial Transplant ,2000,15( Suppl 3) :27 ~ 33.
  • 9Tarng DC, Huaang TP, Chen TW, et al. Erythropoietin hyporesponsiveness:from iron deficiency to iron overload[J]. Kidney int, 1999,55 (1):107~118.
  • 10Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate[ J]. Semin Dial, 2000,13(3) :381 ~ 384.

二级参考文献18

  • 1[1]Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant, 1998, 13(Suppl 2):3-8
  • 2[2]Wagstaff AJ. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Drugs Aging,1995, 7(2):131-56
  • 3[3]House AA, Pham B,Pag DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant, 1996, 13(7):1763-9
  • 4[4]Jones MA,Kingswood JC,Dallyn PE, et al. Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin. Clin Exp Hypertens ,1996, 18(1):51-64
  • 5[5]Sundal E,Kaeser U.Correction of anaemia of chronic renal failure with recombinant human erythropoietin:safety and efficacy of one year's treatment in a European Multicentre Study of 150 haemodiaysis-dependent patients.Nephrol Dial Transplant,1989,4:979-987
  • 6[6]Parker KP,Mitch WE, Stivelman JC, et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodiaysis patients. J Am Soc Nephrol,1997,8:288-293
  • 7[7]Eschbanh JW.The anemia of chronic renal failure:Pathophysiology and effects of recombinant erythropoietin. Kidney Int,1989,35:134-148
  • 8[8]Winearls CG,Oliver DO,Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemian of patients maintained by chronec haemodialysis. Lanct,1986,2:1175-1178
  • 9EschbachJW,EgrieJC,DowningMR.Correctionoftheanemiaofend-stagerenaldiseasewithrecombinanthumanerythropoietin[].The New England Journal of Medicine.1987
  • 10MacdougallIC.Monitoringofironstatusandironsupplementationinpatientstreatedwitherythropoietin[].CurrOpinionNephrolHy-pertens.1994

共引文献130

同被引文献14

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部